GLP-1 (S)
FDA ApprovedStrong EvidenceSemaglutide — GLP-1 Receptor Agonist
Vendor shorthand for Semaglutide — a long-acting GLP-1 receptor agonist FDA-approved as Ozempic and Wegovy.
Half-Life
~1 week
Molecular Weight
4113.6 g/mol
GLP-1 (S) is a vendor shorthand designation for Semaglutide, where 'S' refers to Semaglutide. GLP-1 is the incretin hormone that semaglutide mimics. FDA-approved as Ozempic (type 2 diabetes, cardiovascular risk reduction) and Wegovy (chronic weight management). The STEP trials demonstrated ~15% mean weight reduction; the SELECT trial showed 20% reduction in major cardiovascular events in non-diabetic obese adults. See Semaglutide profile for complete details.
Also Known As
Amino Acid Sequence
Modified GLP-1 analog with C18 fatty diacid conjugation
Reconstitution
See Semaglutide profile. Research peptide: reconstitute with bacteriostatic water.
Open Reconstitution Calculator →